The treatment of brain diseases has long been a challenge in medicine. The blood-brain barrier (BBB) is a natural defense that prevents most drugs from effectively reaching the brain. While essential for protecting the central nervous system, the BBB complicates drug development, leading to a clinical translation rate for brain therapeutics that is significantly lower than in other fields. This situation highlights the urgent need for innovative solutions. While traditional delivery methods continue to improve, emerging technologies in drug delivery offer a new hope. These strategies, ranging from non-invasive routes to localized invasive techniques and bioengineering-based systems, aim to enhance drug delivery efficiency, reduce systemic side effects, and provide new treatment possibilities. This article explores the definitions, advantages, and clinical potential of these delivery strategies in brain disease therapy.
Haumann, Rianne, et al. "Overview of current drug delivery methods across the blood–brain barrier for the treatment of primary brain tumors." CNS drugs 34.11 (2020): 1121-1131.
1. Non-Invasive Drug Delivery Routes
Non-invasive drug delivery methods administer medications to the brain through nasal, oral mucosal, inhalation, or transdermal routes. By avoiding surgical intervention, these approaches significantly improve patient compliance and bypass first-pass metabolism and gastrointestinal degradation, thereby enhancing drug bioavailability and efficacy.
Nasal Delivery: The highly vascularized nasal mucosa allows drugs to bypass the BBB via the olfactory and trigeminal nerves. Notable examples include Zavzpret, a nasal spray for migraine treatment, and emerging exosome-based nasal sprays for Alzheimer's disease.
Oral Mucosal Delivery: The rich capillary network in the oral mucosa facilitates rapid absorption while bypassing gastrointestinal breakdown. For instance, Kynmobi, a sublingual apomorphine film, is used to treat acute "off" episodes in Parkinson's disease.
Inhalation Delivery: Drugs administered via pulmonary mucosa rapidly enter the bloodstream. Adasuve, an inhaled powder formulation of loxapine, provides rapid control of acute agitation.
Transdermal Delivery: This method maintains steady plasma drug levels through sustained release. The Adlarity patch, delivering donepezil weekly, has gained popularity for its convenience in Alzheimer's disease management.
These non-invasive methods not only improve patient experience but also show significant potential in treating neurodegenerative and acute brain disorders.
2. Invasive Localized Drug Delivery Routes
Invasive localized drug delivery methods bypass the BBB by directly administering drugs to specific brain regions. These techniques achieve high local drug concentrations and include intraventricular injection, convection-enhanced delivery (CED), and intrathecal injection.
Intraventricular Injection :This method involves surgically implanted reservoirs to deliver drugs into the brain's ventricles, used for diseases where large molecules struggle to cross the BBB, such as Brineura for neuronal ceroid lipofuscinosis type 2.
Intrathecal Injection : Administering drugs into the cerebrospinal fluid via the subarachnoid space ensures widespread brain distribution. Intrathecal rituximab has shown efficacy in refractory anti-NMDAR encephalitis, significantly reducing cerebrospinal fluid antibody titers.
Convection-Enhanced Delivery (CED) : This technique employs pressure-driven infusion to achieve precise, uniform drug distribution within brain lesions. CED is particularly effective for localized brain conditions such as Parkinson's disease and glioblastoma. In Parkinson's therapy, CED has been used to deliver glial cell line-derived neurotrophic factor (GDNF) via adeno-associated viral vectors to the putamen, restoring dopaminergic function. In glioblastoma, CED delivers drugs via micro-infusion pumps directly to the tumor site, reducing systemic side effects and improving local drug concentration.
Nash, Kevin R., and Marcia N. Gordon. "Convection enhanced delivery of recombinant adeno-associated virus into the mouse brain." Gene Therapy for Neurological Disorders: Methods and Protocols (2016): 285-295.
CED stands out for its precision and effectiveness in treating brain diseases, and its clinical potential will expand with advancements in imaging-guided techniques.
3. Emerging Drug Delivery Systems
Emerging drug delivery systems leverage advances in bioengineering and material sciences to achieve targeted and efficient brain drug delivery through receptor-mediated transcytosis, cell homing effects, and ultrasound-assisted techniques.
Receptor-Mediated Transcytosis: This system uses receptors like transferrin to transport large molecules across the BBB. Izcargo, developed for mucopolysaccharidosis, exemplifies the potential of this strategy.
Cell Homing Technologies: Leveraging the natural migratory abilities of immune cells, these technologies target inflamed brain regions. MAT2203, an antifungal agent, effectively treats cryptococcal meningitis by enhancing efficacy while reducing peripheral toxicity.
Ultrasound-Assisted Delivery: Focused ultrasound temporarily and reversibly disrupts the BBB, facilitating large molecule entry. The combination of aducanumab with ultrasound has shown promise in clearing amyloid-beta plaques in Alzheimer's disease.
These novel systems offer the potential to overcome the limitations of traditional delivery methods, providing new avenues for precision and personalized brain disease treatment.
Research in brain drug delivery represents not only a technological breakthrough but also a response to patient needs. From optimizing non-invasive delivery routes like nasal, oral, inhalation, and transdermal methods to achieving precision through intraventricular injection, CED, and intrathecal administration, each technique advances brain disease therapy. Moreover, receptor-mediated systems, cell homing technologies, and ultrasound-assisted delivery present new strategies for individualized treatment and precision medicine.
As advancements in biomaterials, nanotechnology, and imaging continue, drug delivery will become more efficient, safe, and personalized, benefiting more patients. The pursuit of overcoming the BBB is reshaping the possibilities for brain disease treatment, marking a new era in neuroscience .
